ResultsIQ › Latest results › Onesource Specialty Pharma Limited
Onesource Specialty Pharma Limited Q2 FY27 earnings call summary
NSE: ONESOURCE · BSE: 544292
Earnings call of 27 Oct 2026, summarised by AI from the filing.
OneSource reaffirmed FY28 guidance of $400 million revenue and $160 million EBITDA after Q2 FY27 revenue of more than ₹5 billion, up 37% year-on-year.
Key takeaways
- FY28 guidance Reaffirmed at $400 million revenue and $160 million EBITDA, on all 3 DDC lines being available for FY28.
- Line 2 Second cartridge line operational since September, doubling sterile production days after a delay of about 6 months.
- Semaglutide Hikma launched the first generic semaglutide in Saudi Arabia and Dr. Reddy's API supply has commenced.
- Line 3 timing Line 3 qualification is lengthy; start targeted Q4 FY27 but commercialisation may slip to start of FY28.
Onesource Specialty Pharma Limited H1 FY27 results
As filed: Revenue ₹961 cr, EBITDA ₹273 cr, PAT ₹137 cr, EBITDA margin 28.4%.
Not scored. No result for the same half-year last year.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹449 cr (+37% year on year), EBITDA ₹123 cr (+39% year on year), PAT ₹25.0 cr, EBITDA margin 27.5% (+25 bps). Score 77 of 100, Above trend. EBITDA margin rose 25 bps year on year. Tax rate -23%. Not enough history for a trend yet: scored on growth alone. Share price after the results: −7.2% in 28 days (Nifty 500: +2.7%).
- Q4 FY26: Revenue ₹428 cr (+1% year on year), EBITDA ₹91.9 cr (−49% year on year), PAT ₹4.6 cr (−100% year on year), EBITDA margin 21.5% (−1,000 bps). Score 9 of 100, Below trend. EBITDA margin fell 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −9.9% in 30 days (Nifty 500: +1.0%).
- Q3 FY26: Revenue ₹290 cr (−26% year on year), EBITDA ₹17.3 cr (−88% year on year), PAT −₹88.7 cr, EBITDA margin 6.0% (−1,000 bps). Score 0 of 100, Below trend. EBITDA margin fell 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 23% from last quarter. Share price after the results: −12.5% in 28 days (Nifty 500: +3.0%).
- Q2 FY26: Revenue ₹376 cr (+300% year on year), EBITDA ₹107 cr, PAT ₹10.0 cr, EBITDA margin 28.5% (+1,000 bps). Score 88 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Other income 50% of PBT. Tax rate -83%. Not enough history for a trend yet: scored on growth alone. Share price after the results: −5.6% in 30 days (Nifty 500: −0.6%).
- Q1 FY26: Revenue ₹321 cr, EBITDA ₹80.0 cr, PAT ₹25.0 cr, EBITDA margin 24.9%. Not scored. No result for the same quarter last year. Share price after the results: −1.0% in 30 days (Nifty 500: 0.0%).
- Q4 FY25: Revenue ₹477 cr, EBITDA ₹237 cr, PAT ₹174 cr, EBITDA margin 49.7%. Not scored. No result for the same quarter last year. Share price after the results: +17.5% in 30 days (Nifty 500: +2.8%).
- Q3 FY25: Revenue ₹337 cr, EBITDA ₹101 cr, PAT −₹73.0 cr, EBITDA margin 30.0%. Not scored. No result for the same quarter last year.
Past price moves after results do not indicate future moves. Not a recommendation.
Onesource Specialty Pharma Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (27 Oct 2026), Results press release (27 Oct 2026)
- Q1 FY27: Earnings call (25 Jul 2026), Results press release (24 Jul 2026)
- Q4 FY26: Earnings call (13 May 2026), Results deck (13 May 2026), Results press release (13 May 2026)
- Q3 FY26: Earnings call (24 Jan 2026)
- Q2 FY26: Earnings call (12 Nov 2025), Results deck (12 Nov 2025), Results press release (11 Nov 2025)
- Q1 FY26: Earnings call (5 Aug 2025)
- Q4 FY25: Earnings call (6 May 2025)
- Other events: Investor presentation (3 Sep 2026), Strategy deck (26 Sep 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.